Patient group characteristics
| Parameters . | T-ALL (n = 71) . | Precursor B-ALL (n = 210) . |
|---|---|---|
| Treatment group distribution | ||
| SRG (%) | 0 | 62 (30) |
| MRG (%) | 50 (70) | 135 (64) |
| HRG (%) | 21 (30) | 13 (6) |
| Sex | ||
| Male (%) | 56 (79) | 109 (52) |
| Female (%) | 15 (21) | 101 (48) |
| Age distribution in months | ||
| Mean (range) | 104 (0-200) | 64 (10-204) |
| WBC count at diagnosis | ||
| Median × 109/L (range) | 87 (3-700) | 12 (1-550) |
| Prednisone response | ||
| Good (%) | 54 (76) | 200 (95) |
| Poor (%) | 17 (24) | 10 (5) |
| Five-year RFS rates (%)*(no. relapses) | ||
| SRG | – | 84 (10) |
| MRG | 75 (12) | 78 (30) |
| HRG | 24 (16) | 23 (10) |
| All patients | 60 (28) | 76 (50) |
| Parameters . | T-ALL (n = 71) . | Precursor B-ALL (n = 210) . |
|---|---|---|
| Treatment group distribution | ||
| SRG (%) | 0 | 62 (30) |
| MRG (%) | 50 (70) | 135 (64) |
| HRG (%) | 21 (30) | 13 (6) |
| Sex | ||
| Male (%) | 56 (79) | 109 (52) |
| Female (%) | 15 (21) | 101 (48) |
| Age distribution in months | ||
| Mean (range) | 104 (0-200) | 64 (10-204) |
| WBC count at diagnosis | ||
| Median × 109/L (range) | 87 (3-700) | 12 (1-550) |
| Prednisone response | ||
| Good (%) | 54 (76) | 200 (95) |
| Poor (%) | 17 (24) | 10 (5) |
| Five-year RFS rates (%)*(no. relapses) | ||
| SRG | – | 84 (10) |
| MRG | 75 (12) | 78 (30) |
| HRG | 24 (16) | 23 (10) |
| All patients | 60 (28) | 76 (50) |
Significant differences were found between T-ALL and precursor B-ALL for all parameters (P ≤ .001).
Median relapse-free follow-up time of CCR patients is 63 months for T-ALL and 72 months for precursor B-ALL.